Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 2.76 USD 1.47% Market Closed
Market Cap: 815.2m USD
Have any thoughts about
Abcellera Biologics Inc?
Write Note

Abcellera Biologics Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Abcellera Biologics Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Abcellera Biologics Inc
NASDAQ:ABCL
Stock-Based Compensation
$64.2m
CAGR 3-Years
97%
CAGR 5-Years
154%
CAGR 10-Years
N/A
Arch Biopartners Inc
XTSX:ARCH
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abcellera Biologics Inc
Glance View

Market Cap
802.7m USD
Industry
Life Sciences Tools & Services

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

ABCL Intrinsic Value
1.67 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Abcellera Biologics Inc's Stock-Based Compensation?
Stock-Based Compensation
64.2m USD

Based on the financial report for Dec 31, 2023, Abcellera Biologics Inc's Stock-Based Compensation amounts to 64.2m USD.

What is Abcellera Biologics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
154%

Over the last year, the Stock-Based Compensation growth was 30%. The average annual Stock-Based Compensation growth rates for Abcellera Biologics Inc have been 97% over the past three years , 154% over the past five years .

Back to Top